Filing Flows › International Stem Cell (ISCO) › Q4 2025
International Stem Cell (ISCO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 30, 2026
International Stem Cell (ISCO) reported revenue of $2.2M for the fourth quarter 2025 (Q4 2025), -12% from a year earlier and -9% from the quarter before. Operating margin was -14.5%, net loss $348K (16.1% of revenue).
International Stem Cell, Q4 2025: revenue $2.2M (-12% year over year), operating margin -14.5%, net loss $348K, operating cash flow $32K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.2M | -9% | -12% |
| Operating profit | −$313K | -433% | -714% |
| Net earnings | −$348K | -711% | -3264% |
| Operating cash flow | $32K | -35% | — |
| Free cash flow | $29K | -37% | — |
What changed
Revenue was $2.2M in Q4 2025, down 12% year over year and down 9% from the previous quarter. Biomedical Market was the largest line at 93% of revenue.
Operating costs exceeded revenue by $313K, an operating margin of -14.5%. Total costs grew 3% against a revenue fall of 12%. The quarter ended with a net loss of $348K, after a profit of $57K the previous quarter.
Operating cash flow was $32K. Non-cash charges added back $54K of depreciation and amortization and $64K of share-based compensation. Working capital and other items added $262K. Capital expenditures of $3K left free cash flow of $29K.
Questions
What was International Stem Cell's revenue in the fourth quarter 2025?
International Stem Cell (ISCO) reported revenue of $2.2M for the fourth quarter 2025 (Q4 2025), -12% from a year earlier and -9% from the quarter before.
Was International Stem Cell profitable in the fourth quarter 2025?
Operating loss was $313K (-14.5% of revenue) and net loss $348K.